# GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects

> **NCT06964711** · PHASE1 · COMPLETED · sponsor: **Beijing Greatway Pharmaceutical Technology Co.,Ltd.** · enrollment: 92 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** GW117 ODT
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06964711
- **Lead sponsor:** Beijing Greatway Pharmaceutical Technology Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-12
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-03-24
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06964711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06964711, "GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06964711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*